LEESBURG, Va.– Resonant Clinical Solutions has appointed Dr. Christophe Berthoux as its new Chief Executive Officer, the company announced Tuesday. The move marks a major step in the company’s post-acquisition expansion strategy under private equity firm Audax Group.
A veteran of the pharmaceutical services industry, Berthoux brings more than 30 years of experience in clinical research, preclinical services, and patient recruitment. He most recently served as CEO of NAMSA, where he oversaw significant growth through both acquisitions and internal expansion. His prior leadership roles include CEO positions at Synexus and CitoxLab, as well as nearly two decades in senior leadership at Charles River Laboratories, where he ultimately served as Chief Commercial Officer.
“We are thrilled to welcome Christophe to Resonant,” said David Wong, Partner at Audax. “His track record of scaling global pharmaceutical-services businesses makes him the ideal leader to drive Resonant’s next phase of growth.”
Resonant provides outsourced clinical trial services, including trial kitting, equipment and ancillary support, and biorepository management. The company has operated under its own banner since Audax acquired it from Avantor in 2024 and has since invested heavily in infrastructure, operational improvements, and customer service initiatives aimed at global expansion.
Berthoux expressed enthusiasm about the opportunity to lead the company through its next chapter. “Resonant and its respected brands have a strong history of excellence in customer service and clinical trial support,” he said. “I look forward to working with the team to build on this foundation and expand our value to customers worldwide.”
His appointment comes as Resonant positions itself to scale operations across domestic and international markets, aiming to become a more competitive player in the global clinical trial services sector.
